A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)

Condition(s) targeted: Chronic Obstructive Pulmonary Disease

Intervention: Foster® 100/6 µg/unit dose (Drug); Symbicort® Turbohaler® 200/6 μg/actuation (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Chiesi Farmaceutici S.p.A.

Official(s) and/or principal investigator(s):
Dirkje Postma, MD, Study Chair, Affiliation: Dept. of Pulmonary Medicine and Tuberculosis - University of Groningen - The Netherlands
Marteen van den Berge, MD, Principal Investigator, Affiliation: Dept. of Pulmonary Medicine and Tuberculosis - University of Groningen - The Netherlands

Overall contact:
Eddi Bindi, Phone: +390521279764, Email: e.bindi@chiesigroup.com

The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b. i.d.) versus large particles Symbicort® 200/6 (two inhalations b. i.d.), in terms of residual volume reduction over a 12-week treatment period in Chronic Obstructive Pulmonary Disease (COPD) patients.

Official title: A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Symbicort® 200/6 (Budesonide 200 µg Plus Formoterol 6 µg/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstructive Pulmonary Disease.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change from baseline to end of treatment in post-dose residual volume.

Secondary outcome:

Changes from baseline in FEV1, FVC, FEV1/FVC, IVC/FVC, RV, TLC, RV/TLC, FRC, FRC/TLC, RV/VC, Raw, eff and sGaw, eff.

Changes from baseline in airways resistance (R5, R20, R5-20) and reactance at 5 Hertz (X5) (in a subset of at least 50% of patients from pre-selected sites);

Changes from baseline in COPD symptom scores (for each single score and the total score);

Change from baseline in percentage of COPD symptom-free days;

Change from baseline in rescue salbutamol or ipratropium bromide consumption (puffs per day);

Change from baseline in percentage of rescue salbutamol or ipratropium bromide-free days;

Transition Dyspnoea Index (TDI) score;

Clinical COPD Questionnaire (CCQ);

Physical activity (by means of pedometer);

Nasal brushing (mRNA expression);

Number of patients with COPD exacerbations.

Detailed description: Chronic obstructive pulmonary disease (COPD) is an incurable, debilitating and progressive disease that can be fatal. The recent Global Burden of Disease Study ranks COPD as the 6th leading cause of mortality and the 12th leading cause of morbidity world-wide. Furthermore, trends in the use of medical care resources indicate that the economic cost of COPD continues to rise in direct relation to the ageing population, the increase in prevalence of disease and the cost of new and existing medical and public health interventions.

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Male or female patients aged ≥ 40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure or when applicable written informed consent obtained by legal representative.

2. Outpatients with a clinical diagnosis of moderate to severe COPD and including:

1. Smoking history of at least 10 pack years defined as [(number of cigarettes smoked per day) x (number of years of smoking)] / 20, both current and ex-smokers are eligible.

2. Regular use of bronchodilators (e. g. β2-agonist, anticholinergics) in the 2 months before visit 1.

3. Post-bronchodilator FEV1 < 65% of the predicted normal value at visit 1.

4. Post-bronchodilator FEV1/FVC < 0. 7 at visit 1.

5. An increase in FEV1 < 15% and < 200 mL from baseline following administration of 400 µg of salbutamol at visit 1.

6. Plethysmographic Functional Residual Capacity (FRC) > 120% of the predicted normal value (at visit 1 and visit 2).

7. A Baseline Dyspnoea Index (BDI) focal score less or equal to 10 (at visit 1 and at visit 2).

3. A cooperative attitude and ability to be trained to the proper use of pMDI and DPI (Turbohaler®, inspiratory flow-driven, multidose powder inhaler) inhalers.

Main Exclusion Criteria:

1. Diagnosis of asthma or other clinically or functionally relevant respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator's opinion.

2. Clinically unstable concurrent disease: e. g. hyperthyroidism, diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; cardiovascular disease (e. g. coronary artery disease, hypertension, heart failure); gastrointestinal disease (e. g. active peptic ulcer); neurological disease; haematological disease; autoimmune disorders, or other which may impact the evaluation of the results of the study according to investigator's judgement.

3. Patients with COPD exacerbation and/or symptomatic infection of the airways requiring antibiotic therapy (at least 5 days) in the 2 months prior to screening and during the study period.

4. Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period.

5. Major surgery in the previous 3 months and during the trial which may affect patient's compliance in study procedures (e. g. plethysmography).

6. Patients requiring chronic mechanical ventilation for COPD.

Eddi Bindi, Phone: +390521279764, Email: e.bindi@chiesigroup.com

Department of Pulmonary Diseases - University Medical Center Groningen, Groningen 9713, Netherlands; Recruiting
Dirkje Postma, MD, Phone: +31503613532, Email: d.s.postma@long.umcg.nl
Marteen van de Berge, MD, Phone: +31503615260, Email: m.van.den.berge@long.umcg.nl

Starting date: September 2011
Last updated: October 3, 2011